RxDoctor Payments Data

Yvonne Baum, MD

Internal Medicine · Tyler, TXNPI 1679572614

Payments from drug & device makers

$1,918in general payments, 2019–2025

Across 281 payments — averaging $6.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$953
  • Supernus Pharmaceuticals, Inc.$373
  • Avanir Pharmaceuticals, Inc.$221
  • Novo Nordisk$145
  • Currax Pharmaceuticals LLC$50
  • Pfizer$38
  • plus $137 from 9 others

What the payments were for

  • Food & beverage$1,86897%
  • Education$503%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,918 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$95,889
Medicare patients
293
Services billed
1,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide157$249,571
MounjaroTirzepatide90$112,556
JardianceEmpagliflozin61$65,535
EliquisApixaban54$49,524
RybelsusSemaglutide27$45,983
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$22,826
XareltoRivaroxaban22$18,850
MyrbetriqMirabegron19$17,174
GemtesaVibegron19$16,596
AuvelityDextromethorphan Hbr/Bupropion11$12,289
JanuviaSitagliptin Phosphate14$9,861
Repatha SureclickEvolocumab13$7,071
TrintellixVortioxetine Hydrobromide11$5,489
Gabapentin243$4,946
Mirabegron ErMirabegron11$4,826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$145$295,553184 claims
Boehringer IngelheimJardiance$22$65,53561 claims
PfizerEliquis$38$49,52454 claims
AbbVieSynthroid$953$3,99556 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →